Avidity End Period Cash Flow vs Capital Expenditures Analysis
| RNA Stock | USD 30.11 1.01 3.25% |
Avidity Biosciences financial indicator trend analysis is way more than just evaluating Avidity Biosciences prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Avidity Biosciences is a good investment. Please check the relationship between Avidity Biosciences End Period Cash Flow and its Capital Expenditures accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Avidity Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Avidity Stock refer to our How to Trade Avidity Stock guide.
End Period Cash Flow vs Capital Expenditures
End Period Cash Flow vs Capital Expenditures Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Avidity Biosciences End Period Cash Flow account and Capital Expenditures. At this time, the significance of the direction appears to have strong relationship.
The correlation between Avidity Biosciences' End Period Cash Flow and Capital Expenditures is 0.61. Overlapping area represents the amount of variation of End Period Cash Flow that can explain the historical movement of Capital Expenditures in the same time period over historical financial statements of Avidity Biosciences, assuming nothing else is changed. The correlation between historical values of Avidity Biosciences' End Period Cash Flow and Capital Expenditures is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which End Period Cash Flow of Avidity Biosciences are associated (or correlated) with its Capital Expenditures. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Expenditures has no effect on the direction of End Period Cash Flow i.e., Avidity Biosciences' End Period Cash Flow and Capital Expenditures go up and down completely randomly.
Correlation Coefficient | 0.61 |
| Relationship Direction | Positive |
| Relationship Strength | Significant |
End Period Cash Flow
Capital Expenditures
Capital Expenditures are funds used by Avidity Biosciences to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Avidity Biosciences operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most indicators from Avidity Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Avidity Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Avidity Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Avidity Stock refer to our How to Trade Avidity Stock guide.The current year's Selling General Administrative is expected to grow to about 56.9 M, whereas Issuance Of Capital Stock is forecasted to decline to about 221.3 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Research Development | 101.2M | 150.4M | 191.0M | 200.5M | Total Revenue | 9.3M | 9.2M | 9.6M | 6.4M |
Avidity Biosciences fundamental ratios Correlations
Click cells to compare fundamentals
Avidity Biosciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Avidity Biosciences fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 96.9M | 333.9M | 427.6M | 638.8M | 628.6M | 660.0M | |
| Other Current Liab | 1.3M | 10.9M | 28.0M | 60.9M | 36.2M | 20.9M | |
| Total Current Liabilities | 10.2M | 14.6M | 29.7M | 51.9M | 80.7M | 84.7M | |
| Total Stockholder Equity | (65.4M) | 306.2M | 381.4M | 578.1M | 500.8M | 525.8M | |
| Other Liab | 15.1M | 12.2M | 6.5M | 1.2M | 1.1M | 1.1M | |
| Accounts Payable | 2.3M | 7.7M | 2.8M | 4.6M | 8.8M | 4.5M | |
| Cash | 94.6M | 328.1M | 405.5M | 340.4M | 185.1M | 189.2M | |
| Other Assets | 600K | 298K | 850K | 849K | 1.0 | 0.95 | |
| Other Current Assets | 1.1M | 3.5M | 5.6M | 8.3M | 14.9M | 15.6M | |
| Total Liab | 162.3M | 27.7M | 46.2M | 60.7M | 127.8M | 70.7M | |
| Common Stock | 1K | 4K | 5K | 7K | 8K | 7.6K | |
| Property Plant Equipment | 631K | 1.9M | 15.6M | 15.0M | 17.3M | 18.1M | |
| Short Long Term Debt Total | 4.9M | 938K | 10.0M | 10.7M | 9.9M | 8.6M | |
| Net Tangible Assets | (65.4M) | 306.2M | 381.4M | 578.1M | 664.8M | 698.0M | |
| Property Plant And Equipment Net | 631K | 1.5M | 15.6M | 15.0M | 16.7M | 9.2M | |
| Net Debt | (89.6M) | (327.2M) | (395.6M) | (329.7M) | (175.2M) | (184.0M) | |
| Retained Earnings | (22.2M) | (66.5M) | (184.5M) | (358.5M) | (570.8M) | (542.2M) | |
| Non Current Assets Total | 1.2M | 2.2M | 16.4M | 15.9M | 17.2M | 9.9M | |
| Non Currrent Assets Other | 600K | 501K | 599K | 598K | 596K | 537.5K | |
| Cash And Short Term Investments | 94.6M | 328.1M | 405.5M | 610.7M | 595.4M | 373.5M | |
| Common Stock Shares Outstanding | 37.5M | 21.7M | 41.4M | 52.2M | 73.0M | 45.2M | |
| Liabilities And Stockholders Equity | 96.9M | 333.9M | 427.6M | 638.8M | 628.6M | 390.4M | |
| Non Current Liabilities Total | 152.0M | 13.1M | 16.5M | 8.8M | 47.1M | 37.1M | |
| Capital Lease Obligations | 393K | 938K | 11.7M | 7.6M | 9.9M | 5.6M | |
| Other Stockholder Equity | (43.2M) | 38.9M | 566.2M | 939.3M | 1.1B | 1.1B | |
| Net Invested Capital | (60.8M) | 306.2M | 381.4M | 578.1M | 500.8M | 307.1M | |
| Property Plant And Equipment Gross | 631K | 1.5M | 15.6M | 15.0M | 21.9M | 23.0M | |
| Total Current Assets | 95.7M | 331.7M | 411.1M | 622.9M | 611.3M | 380.6M | |
| Accumulated Other Comprehensive Income | (134.7M) | (5K) | (187K) | (2.7M) | 125K | 131.3K | |
| Capital Stock | 0.0 | 4K | 5K | 7K | 8K | 7.6K | |
| Net Working Capital | 85.4M | 317.1M | 381.5M | 571.0M | 530.6M | 345.5M | |
| Short Term Debt | 2.8M | 7.7M | 3.5M | 6.2M | 7.3M | 5.6M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Avidity Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Avidity Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Avidity Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Avidity Biosciences Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Avidity Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Avidity Stock refer to our How to Trade Avidity Stock guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avidity Biosciences. If investors know Avidity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avidity Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.88) | Revenue Per Share 0.103 | Quarterly Revenue Growth (0.17) | Return On Assets (0.18) | Return On Equity (0.28) |
The market value of Avidity Biosciences is measured differently than its book value, which is the value of Avidity that is recorded on the company's balance sheet. Investors also form their own opinion of Avidity Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Avidity Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avidity Biosciences' market value can be influenced by many factors that don't directly affect Avidity Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avidity Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avidity Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avidity Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.